London is a bad place to raise money, says life sciences tsar Sir John Bell [Yahoo! Finance]
Barinthus Biotherapeutics plc - American Depositary Shares (BRNS)
Company Research
Source: Yahoo! Finance
Sir John, an industry veteran known for his critical role steering the Covid vaccine rollout, said British biotech businesses “are all going to pack up and go somewhere else” if the UK's equity markets do not become a better place to raise money. The comments come just days after two British drug discovery companies announced they were quitting London's junior market . On April 2 Redx Pharma unveiled plans to delist from the Alternative Investment Market (Aim), claiming its low valuation was “not conducive” to raising cash to spend on more treatments. It echoed an announcement from C4X Discovery a week earlier where it said it was leaving Aim because the recent downturn in the financial markets “adversely impacted our share price, and with it, our future ability to raise funds in the public markets”. The moves have sparked fresh concerns over the health of the UK capital markets . The London Stock Exchange has been struck by a spate of exits over the past year, including travel g
Show less
Read more
Impact Snapshot
Event Time:
BRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BRNS alerts
High impacting Barinthus Biotherapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BRNS
News
- Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsGlobeNewswire
- Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerGlobeNewswire
- Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections [Yahoo! Finance]Yahoo! Finance
BRNS
Earnings
- 5/13/24 - Beat
BRNS
Analyst Actions
- 4/19/24 - HC Wainwright